Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS
· Delayed Price · Currency is USD
0.0493
+0.0033 (7.07%)
At close: Dec 5, 2025
Adaptimmune Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -169.76 | -70.81 | -113.87 | -165.46 | -158.09 | -130.09 | Upgrade
|
| Depreciation & Amortization | 10.63 | 11.23 | 9.84 | 6.08 | 6.57 | 7.59 | Upgrade
|
| Asset Writedown & Restructuring Costs | 10.4 | 10.4 | - | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -1.73 | -1.27 | -1.99 | 2.53 | 5.28 | 3.84 | Upgrade
|
| Stock-Based Compensation | 7.88 | 12.05 | 11.77 | 18.24 | 20.63 | 10.41 | Upgrade
|
| Other Operating Activities | 1.61 | 2.18 | -21.68 | -1.62 | 1.71 | -1.39 | Upgrade
|
| Change in Accounts Receivable | -0.18 | 29.77 | -1.29 | -9.81 | -19.36 | 1.75 | Upgrade
|
| Change in Inventory | -11.4 | -7.36 | - | - | - | - | Upgrade
|
| Change in Accounts Payable | -2.8 | 9.62 | -9.09 | 4.41 | 4.21 | 3.87 | Upgrade
|
| Change in Unearned Revenue | -36.36 | -69.8 | -14.57 | 3.87 | 149.79 | 47.97 | Upgrade
|
| Change in Other Net Operating Assets | 1.68 | 0.79 | - | - | - | 2.46 | Upgrade
|
| Operating Cash Flow | -190.03 | -73.21 | -140.88 | -141.77 | 10.73 | -53.59 | Upgrade
|
| Capital Expenditures | -1.64 | -0.89 | -4.68 | -29.5 | -8.57 | -2.34 | Upgrade
|
| Cash Acquisitions | - | - | 45.26 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -1.25 | -1.83 | -0.2 | -0.24 | -0.21 | -0.57 | Upgrade
|
| Investment in Securities | 4.5 | -56.36 | 135.03 | 118.88 | 84.58 | -276.02 | Upgrade
|
| Other Investing Activities | 0.18 | 0.13 | 1.12 | - | - | - | Upgrade
|
| Investing Cash Flow | 1.79 | -58.95 | 176.54 | 89.14 | 75.8 | -278.92 | Upgrade
|
| Long-Term Debt Issued | - | 49.5 | - | - | - | - | Upgrade
|
| Net Debt Issued (Repaid) | -0.45 | 49.5 | - | - | - | - | Upgrade
|
| Issuance of Common Stock | 1.79 | 29.25 | 0.88 | 12.87 | 3.29 | 340.05 | Upgrade
|
| Financing Cash Flow | 1.34 | 78.75 | 0.88 | 12.87 | 3.29 | 340.05 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | -0.4 | 0.88 | -2.3 | 0.37 | -0.96 | Upgrade
|
| Net Cash Flow | -186.9 | -53.81 | 37.42 | -42.06 | 90.18 | 6.58 | Upgrade
|
| Free Cash Flow | -191.67 | -74.09 | -145.56 | -171.27 | 2.16 | -55.93 | Upgrade
|
| Free Cash Flow Margin | -294.49% | -41.62% | -241.47% | -630.86% | 35.05% | -1413.14% | Upgrade
|
| Free Cash Flow Per Share | -0.74 | -0.29 | -0.72 | -1.06 | 0.01 | -0.39 | Upgrade
|
| Cash Interest Paid | 2.09 | 2.09 | - | - | - | - | Upgrade
|
| Cash Income Tax Paid | 1.53 | 1.53 | 4 | 0.63 | 0.54 | 0.08 | Upgrade
|
| Levered Free Cash Flow | -123.19 | 2.17 | -69.17 | -111.24 | -75.01 | -62.81 | Upgrade
|
| Unlevered Free Cash Flow | -119.65 | 4.26 | -69.17 | -111.24 | -75.01 | -62.81 | Upgrade
|
| Change in Working Capital | -49.06 | -36.98 | -24.95 | -1.53 | 134.63 | 56.05 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.